Abbott's first-quarter profit forecast misses estimates, shares dip
Abbott Laboratories on Wednesday forecast first-quarter profit below Wall Street as weakness in nutrition and diagnostics ...
Abbott Laboratories: Solid Performance in Key Sectors but Hold Rating Due to Mixed Outlook
Morgan Stanley analyst Patrick Wood maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday and set a price target of ...
Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.
Abbott Q4 Earnings Meet, Margins Down, Stock Falls in Pre-Market
Abbott Laboratories ABT reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.34, in line with the Zacks ...
Abbott Laboratories: Strong Performance and Promising Outlook Support Buy Rating
Analyst Lee Hambright of Bernstein maintained a Buy rating on Abbott Laboratories (ABT – Research Report), boosting the price target to ...
Crude Oil Edges Lower; Abbott Laboratories Posts Weak Sales
Abbott Laboratories ABT reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11 ...
Abbott pushes toddler milks that can cause health issues: lawsuit
The lawsuit accuses the formula maker of deceptively marketing the milks to make them seem like the next recommended step for toddlers.
Abbott sued over its marketing of potentially harmful toddler milk
Formulas marketed for toddlers are a burgeoning business, but pediatricians have long recommended against their use.
Abbott banks on glucose monitors, new launches to ride out China, currency hit
Abbott Laboratories on Wednesday forecast 2025 profit that came in line with Wall Street estimates as it expects new device ...